Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods ME Klepser, EJ Ernst, RE Lewis, ME Ernst, MA Pfaller Antimicrobial agents and chemotherapy 42 (5), 1207-1212, 1998 | 376 | 1998 |
Unsafe and potentially safe herbal therapies TB Klepser, ME Klepser American Journal of Health-System Pharmacy 56 (2), 125-138, 1999 | 339 | 1999 |
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans ME Klepser, EJ Wolfe, RN Jones, CH Nightingale, MA Pfaller Antimicrobial Agents and Chemotherapy 41 (6), 1392-1395, 1997 | 289 | 1997 |
Osmitopsis asteriscoides (Asteraceae)-the antimicrobial activity and essential oil composition of a Cape-Dutch remedy A Viljoen, S Van Vuuren, E Ernst, M Klepser, B Demirci, H Başer, ... Journal of Ethnopharmacology 88 (2-3), 137-143, 2003 | 281 | 2003 |
Comparison of Etest, chequerboard dilution and time–kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species RE Lewis, DJ Diekema, SA Messer, MA Pfaller, ME Klepser Journal of Antimicrobial Chemotherapy 49 (2), 345-351, 2002 | 257 | 2002 |
Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans EJ Ernst, ME Klepser, MA Pfaller Antimicrobial agents and chemotherapy 44 (4), 1108-1111, 2000 | 237 | 2000 |
In Vitro Activity of Micafungin (FK-463) against Candida spp.: Microdilution, Time-Kill, and Postantifungal-Effect Studies EJ Ernst, EE Roling, CR Petzold, DJ Keele, ME Klepser Antimicrobial agents and chemotherapy 46 (12), 3846-3853, 2002 | 202 | 2002 |
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods EJ Ernst, ME Klepser, ME Ernst, SA Messer, MA Pfaller Diagnostic microbiology and infectious disease 33 (2), 75-80, 1999 | 186 | 1999 |
Assessment of patients' perceptions and beliefs regarding herbal therapies TB Klepser, WR Doucette, MR Horton, LM Buys, ME Ernst, JK Ford, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 20 (1 …, 2000 | 182 | 2000 |
Novel triazole antifungal agents HL Hoffman, EJ Ernst, ME Klepser Expert opinion on investigational drugs 9 (3), 593-605, 2000 | 161 | 2000 |
Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. J Le, ED Ashley, MM Neuhauser, J Brown, C Gentry, ME Klepser, ... Pharmacotherapy 30 (6), 562-584, 2010 | 136 | 2010 |
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill … EE Roling, ME Klepser, A Wasson, RE Lewis, EJ Ernst, MA Pfaller Diagnostic microbiology and infectious disease 43 (1), 13-17, 2002 | 134 | 2002 |
Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination againstCandida albicans by Using a Dynamic In … RE Lewis, BC Lund, ME Klepser, EJ Ernst, MA Pfaller Antimicrobial agents and chemotherapy 42 (6), 1382-1386, 1998 | 126 | 1998 |
In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against Aspergillus, Fusarium, and Scedosporium spp RE Lewis, NP Wiederhold, ME Klepser Antimicrobial agents and chemotherapy 49 (3), 945-951, 2005 | 125 | 2005 |
Evaluation of voriconazole pharmacodynamics using time-kill methodology ME Klepser, D Malone, RE Lewis, EJ Ernst, MA Pfaller Antimicrobial agents and chemotherapy 44 (7), 1917-1920, 2000 | 123 | 2000 |
Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? ME Ernst, EJ Ernst, ME Klepser American journal of health-system pharmacy 54 (22), 2569-2584, 1997 | 117 | 1997 |
Antifungal Resistance Among Candida Species ME Klepser Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (8P2 …, 2001 | 111 | 2001 |
Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy PO Gubbins, ME Klepser, AM Dering-Anderson, KA Bauer, KM Darin, ... Journal of the American Pharmacists Association 54 (2), 163-171, 2014 | 106 | 2014 |
Drug treatment of HIV-related opportunistic infections ME Klepser, TB Klepser Drugs 53 (1), 40-73, 1997 | 91 | 1997 |
The value of amphotericin B in the treatment of invasive fungal infections M Klepser Journal of critical care 26 (2), 225. e1-225. e10, 2011 | 90 | 2011 |